Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.016 AUD | -5.88% | -11.11% | -54.29% |
May. 22 | Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4% | MT |
May. 20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 14.67M 9.74M |
---|---|---|---|---|---|
Net income 2024 * | -13M -8.63M | Net income 2025 * | -21M -13.94M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.79% |
1 day | -5.88% | ||
1 week | -11.11% | ||
Current month | -11.11% | ||
1 month | -40.74% | ||
3 months | -46.67% | ||
6 months | -46.67% | ||
Current year | -54.29% |
Managers | Title | Age | Since |
---|---|---|---|
Phillip Hains
DFI | Director of Finance/CFO | 64 | 23-07-11 |
Chief Tech/Sci/R&D Officer | - | 22-07-04 | |
Li Ren
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lesley Russell
BRD | Director/Board Member | 63 | 20-08-27 |
Paul Hopper
FOU | Founder | 68 | 20-02-01 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 23-07-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 0.016 | -5.88% | 4 006 591 |
24-06-05 | 0.017 | -10.53% | 3,628,735 |
24-06-04 | 0.019 | 0.00% | 3,721,870 |
24-06-03 | 0.019 | +5.56% | 1,556,358 |
24-05-31 | 0.018 | 0.00% | 2,700,412 |
Delayed Quote Australian S.E., June 06, 2024 at 02:10 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-54.29% | 9.74M | |
+18.72% | 125B | |
+14.53% | 109B | |
-2.88% | 24.74B | |
+4.63% | 22.67B | |
-9.65% | 18.14B | |
-41.04% | 16.67B | |
-11.83% | 16.64B | |
+1.46% | 13.45B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- CHM Stock